🎉After 18 months, the commissioning of the Amber Bridge isotope precision packaging laboratory was completed.
🫴We can supply multiple #isotope products such as helium-3/carbon-13/nitrogen-15/oxygen-18.
Provide customized services to meet the packaging needs of different liters.
The bottleneck in #alpha#therapy may no longer be #Ac-225 itself.
As the field scales, success will depend on supply chains, #radiochemistry, quality systems, and #clinical standardization. Powerful #isotopes matter—but reliable infrastructure matters more.
The biggest challenge for At-211 may not be #clinical.
It's supply.
A 7.2-hour half-life means success depends on manufacturing, quality release, logistics, and timing.
In the next era of #nuclear#medicine, isotope infrastructure could become as important as the therapy itself.
#Cu-64 may redefine #nuclear#medicine—not just because it's #theranostic, but because its future depends on something upstream: enriched #Ni-64.
As demand grows, #isotope#enrichment and #supply-chain resilience could become the real competitive edge.
💡The biggest bottleneck in #RPT may no longer be the drug itself. For years, the #radiopharmaceutical industry focused on targets, molecules, and efficacy. But today, a shift is happening: The competition is moving from “who has the better therapy” to “who can secure #isotopes.”
👏Nuclear medicine’s next bottleneck may not be biology — it may be isotope infrastructure.
As PET capacity tightens, copper isotopes like ⁶¹Cu, ⁶⁴Cu, and ⁶⁷Cu are gaining attention for one reason: commercialization.
The next winners may be defined by logistics, not physics.
October 17 — Amber Bridge will be waiting for you at EANM 2026 in Vienna!
Amber Bridge specializes in the research, production, and distribution of isotopes, with years of deep expertise in the field.
Precision defines isotope gas value. From nuclear medicine to semiconductors, blending accuracy—not just materials—drives performance. Tight tolerances demand expert gas preparation, QC, and traceability. Looking for a reliable isotope gas partner? Let’s connect. #StableIsotopes
What if science had no limits?
Infinite supply, zero decay, perfect results.
…Not today.
At Amber Bridge, we believe real innovation is built on precision, reliability, and respect for science.
No tricks. Just science.
Happy April Fools’ Day.
#AprilFoolsDay#NuclearMedicine
High-enrichment Boron-10 (≥99.9%) available in multiple forms. Ideal for reactor control, shielding, and BNCT applications. Stable supply, fast delivery, and consistent quality for global partners.
#Boron10#StableIsotopes#NuclearTechnology#IsotopeSupply
A novel #PSMA PET tracer, [¹⁸F]AlF-H3RESCA-PSMA, enables efficient ¹⁸F labeling under mild conditions, improving #tumor imaging performance. With strong #clinical potential, reliable ¹⁸F production is key—high-enrichment ¹⁸O supply supports both research and production needs.
Depleted Ge-73 supply in GeH₄, GeF₄, and Ge forms.
0.005% abundance, up to 99.9999% purity.
Stock available, fast delivery, competitive pricing.
Used in semiconductors and low-background research.
#Ge73#Isotopes#Semiconductor#HighPurityMaterials
High-quality H₂¹⁸O available: 98% enrichment, ≥99.9% purity.
Suitable for isotope research, tracer studies, and metabolism analysis.
Reliable global supply, compliant export, COA available.
Contact us for details.
#Oxygen18#Isotopes#StableIsotopes#ResearchMaterials
A promising new theranostic strategy for melanoma.
A team led by Prof. Zhibo Liu (Peking University) reported the first SORT1-targeting #theranostic pair in Journal of Medicinal Chemistry: ⁸⁹Zr-DFO-latozinemab for PET imaging and ¹⁷⁷Lu-DOTA-#latozinemab for #targeted therapy.
💨 Boron-10 (¹⁰B) is a key isotope in nuclear science.
Used in #BNCT#cancer therapy, #neutron detection, #radiation shielding, and advanced materials, its strong neutron-capture capability makes it essential for #nuclear#medicine, #reactor technology, and materials research.
A recent EJNMMI Research study shows PNA-mediated #pretargeting with ¹⁶¹Tb reduces systemic radiation exposure.
Using a two-step strategy, blood radioactivity dropped 32-fold while inhibiting tumor growth—offering a safer #therapeutic window for targeted #radionuclide therapy.